The carbonic anhydrase inhibitor acetazolamide exerts antidystonic effects in the dt(sz) mutant hamster
Previous studies suggested an involvement of gamma-aminobutyric acid (GABA)-mediated excitation by an enhanced efflux of bicarbonate ions in addition to retarded development of GABAergic inhibition in the syndrome of dt(sz) mutant hamsters, a model of paroxysmal dyskinesia in which dystonic episodes...
Gespeichert in:
Veröffentlicht in: | European journal of pharmacology 2004-10, Vol.502 (1-2), p.105-108 |
---|---|
Hauptverfasser: | , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 108 |
---|---|
container_issue | 1-2 |
container_start_page | 105 |
container_title | European journal of pharmacology |
container_volume | 502 |
creator | Richter, Angelika Hamann, Melanie |
description | Previous studies suggested an involvement of gamma-aminobutyric acid (GABA)-mediated excitation by an enhanced efflux of bicarbonate ions in addition to retarded development of GABAergic inhibition in the syndrome of dt(sz) mutant hamsters, a model of paroxysmal dyskinesia in which dystonic episodes occur in response to stress. Acetazolamide blocks bicarbonate regeneration in neurons and can thereby reduce GABA-mediating excitation without affecting GABA-mediated inhibition. In the present study, the effects of acetazolamide (15-60 mg/kg, i.p.) on severity of dystonia were therefore examined in dt(sz) hamsters. Acetazolamide significantly reduced the severity of dystonia at a dose of 60 mg/kg. These data are in line with several case reports from patients with paroxysmal dystonia, suggesting that acetazolamide can be useful in the treatment of this movement disorder. The mechanism of the antidystonic efficacy of acetazolamide has to be examined by further studies. |
doi_str_mv | 10.1016/j.ejphar.2004.08.017 |
format | Article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_66941373</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>66941373</sourcerecordid><originalsourceid>FETCH-LOGICAL-p122t-f7245dcf25122696c6d48d67c729078b7492807e3935a5c6d1c9693c8666dde13</originalsourceid><addsrcrecordid>eNo1kMtOwzAQRb0A0VL4A4S8QrBIsB0_4iVCvKRKbMo6cuwJcZVHsR2J9uuJoKxGd-6ZsxiErijJKaHyfpvDdteakDNCeE7KnFB1gpaEUJ4xrfUCnce4JYQIzcQZWlDBJSdaLNHnpgVsTajHwVtshnbvgomA_dD62qcxYGMhmcPYmd47wPANIcUZTN7tY_q9gqYBOy_9gNNsc-k2Hu5wP6WZwq3pY4JwgU4b00W4PM4V-nh-2jy-Zuv3l7fHh3W2o4ylrFGMC2cbJuYotbTS8dJJZRXTRJW14pqVREGhC2HE3FKrpS5sKaV0DmixQjd_3l0YvyaIqep9tNB1ZoBxipWUmtNCFTN4fQSnugdX7YLvTdhX_68pfgDd1GbB</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>66941373</pqid></control><display><type>article</type><title>The carbonic anhydrase inhibitor acetazolamide exerts antidystonic effects in the dt(sz) mutant hamster</title><source>MEDLINE</source><source>Access via ScienceDirect (Elsevier)</source><creator>Richter, Angelika ; Hamann, Melanie</creator><creatorcontrib>Richter, Angelika ; Hamann, Melanie</creatorcontrib><description>Previous studies suggested an involvement of gamma-aminobutyric acid (GABA)-mediated excitation by an enhanced efflux of bicarbonate ions in addition to retarded development of GABAergic inhibition in the syndrome of dt(sz) mutant hamsters, a model of paroxysmal dyskinesia in which dystonic episodes occur in response to stress. Acetazolamide blocks bicarbonate regeneration in neurons and can thereby reduce GABA-mediating excitation without affecting GABA-mediated inhibition. In the present study, the effects of acetazolamide (15-60 mg/kg, i.p.) on severity of dystonia were therefore examined in dt(sz) hamsters. Acetazolamide significantly reduced the severity of dystonia at a dose of 60 mg/kg. These data are in line with several case reports from patients with paroxysmal dystonia, suggesting that acetazolamide can be useful in the treatment of this movement disorder. The mechanism of the antidystonic efficacy of acetazolamide has to be examined by further studies.</description><identifier>ISSN: 0014-2999</identifier><identifier>DOI: 10.1016/j.ejphar.2004.08.017</identifier><identifier>PMID: 15464095</identifier><language>eng</language><publisher>Netherlands</publisher><subject>Acetazolamide - therapeutic use ; Animals ; Carbonic Anhydrase Inhibitors - therapeutic use ; Cricetinae ; Dose-Response Relationship, Drug ; Dystonia - drug therapy ; Dystonia - genetics ; Mutation</subject><ispartof>European journal of pharmacology, 2004-10, Vol.502 (1-2), p.105-108</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/15464095$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Richter, Angelika</creatorcontrib><creatorcontrib>Hamann, Melanie</creatorcontrib><title>The carbonic anhydrase inhibitor acetazolamide exerts antidystonic effects in the dt(sz) mutant hamster</title><title>European journal of pharmacology</title><addtitle>Eur J Pharmacol</addtitle><description>Previous studies suggested an involvement of gamma-aminobutyric acid (GABA)-mediated excitation by an enhanced efflux of bicarbonate ions in addition to retarded development of GABAergic inhibition in the syndrome of dt(sz) mutant hamsters, a model of paroxysmal dyskinesia in which dystonic episodes occur in response to stress. Acetazolamide blocks bicarbonate regeneration in neurons and can thereby reduce GABA-mediating excitation without affecting GABA-mediated inhibition. In the present study, the effects of acetazolamide (15-60 mg/kg, i.p.) on severity of dystonia were therefore examined in dt(sz) hamsters. Acetazolamide significantly reduced the severity of dystonia at a dose of 60 mg/kg. These data are in line with several case reports from patients with paroxysmal dystonia, suggesting that acetazolamide can be useful in the treatment of this movement disorder. The mechanism of the antidystonic efficacy of acetazolamide has to be examined by further studies.</description><subject>Acetazolamide - therapeutic use</subject><subject>Animals</subject><subject>Carbonic Anhydrase Inhibitors - therapeutic use</subject><subject>Cricetinae</subject><subject>Dose-Response Relationship, Drug</subject><subject>Dystonia - drug therapy</subject><subject>Dystonia - genetics</subject><subject>Mutation</subject><issn>0014-2999</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2004</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo1kMtOwzAQRb0A0VL4A4S8QrBIsB0_4iVCvKRKbMo6cuwJcZVHsR2J9uuJoKxGd-6ZsxiErijJKaHyfpvDdteakDNCeE7KnFB1gpaEUJ4xrfUCnce4JYQIzcQZWlDBJSdaLNHnpgVsTajHwVtshnbvgomA_dD62qcxYGMhmcPYmd47wPANIcUZTN7tY_q9gqYBOy_9gNNsc-k2Hu5wP6WZwq3pY4JwgU4b00W4PM4V-nh-2jy-Zuv3l7fHh3W2o4ylrFGMC2cbJuYotbTS8dJJZRXTRJW14pqVREGhC2HE3FKrpS5sKaV0DmixQjd_3l0YvyaIqep9tNB1ZoBxipWUmtNCFTN4fQSnugdX7YLvTdhX_68pfgDd1GbB</recordid><startdate>20041011</startdate><enddate>20041011</enddate><creator>Richter, Angelika</creator><creator>Hamann, Melanie</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>20041011</creationdate><title>The carbonic anhydrase inhibitor acetazolamide exerts antidystonic effects in the dt(sz) mutant hamster</title><author>Richter, Angelika ; Hamann, Melanie</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p122t-f7245dcf25122696c6d48d67c729078b7492807e3935a5c6d1c9693c8666dde13</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2004</creationdate><topic>Acetazolamide - therapeutic use</topic><topic>Animals</topic><topic>Carbonic Anhydrase Inhibitors - therapeutic use</topic><topic>Cricetinae</topic><topic>Dose-Response Relationship, Drug</topic><topic>Dystonia - drug therapy</topic><topic>Dystonia - genetics</topic><topic>Mutation</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Richter, Angelika</creatorcontrib><creatorcontrib>Hamann, Melanie</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>European journal of pharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Richter, Angelika</au><au>Hamann, Melanie</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The carbonic anhydrase inhibitor acetazolamide exerts antidystonic effects in the dt(sz) mutant hamster</atitle><jtitle>European journal of pharmacology</jtitle><addtitle>Eur J Pharmacol</addtitle><date>2004-10-11</date><risdate>2004</risdate><volume>502</volume><issue>1-2</issue><spage>105</spage><epage>108</epage><pages>105-108</pages><issn>0014-2999</issn><abstract>Previous studies suggested an involvement of gamma-aminobutyric acid (GABA)-mediated excitation by an enhanced efflux of bicarbonate ions in addition to retarded development of GABAergic inhibition in the syndrome of dt(sz) mutant hamsters, a model of paroxysmal dyskinesia in which dystonic episodes occur in response to stress. Acetazolamide blocks bicarbonate regeneration in neurons and can thereby reduce GABA-mediating excitation without affecting GABA-mediated inhibition. In the present study, the effects of acetazolamide (15-60 mg/kg, i.p.) on severity of dystonia were therefore examined in dt(sz) hamsters. Acetazolamide significantly reduced the severity of dystonia at a dose of 60 mg/kg. These data are in line with several case reports from patients with paroxysmal dystonia, suggesting that acetazolamide can be useful in the treatment of this movement disorder. The mechanism of the antidystonic efficacy of acetazolamide has to be examined by further studies.</abstract><cop>Netherlands</cop><pmid>15464095</pmid><doi>10.1016/j.ejphar.2004.08.017</doi><tpages>4</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0014-2999 |
ispartof | European journal of pharmacology, 2004-10, Vol.502 (1-2), p.105-108 |
issn | 0014-2999 |
language | eng |
recordid | cdi_proquest_miscellaneous_66941373 |
source | MEDLINE; Access via ScienceDirect (Elsevier) |
subjects | Acetazolamide - therapeutic use Animals Carbonic Anhydrase Inhibitors - therapeutic use Cricetinae Dose-Response Relationship, Drug Dystonia - drug therapy Dystonia - genetics Mutation |
title | The carbonic anhydrase inhibitor acetazolamide exerts antidystonic effects in the dt(sz) mutant hamster |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-19T11%3A35%3A52IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20carbonic%20anhydrase%20inhibitor%20acetazolamide%20exerts%20antidystonic%20effects%20in%20the%20dt(sz)%20mutant%20hamster&rft.jtitle=European%20journal%20of%20pharmacology&rft.au=Richter,%20Angelika&rft.date=2004-10-11&rft.volume=502&rft.issue=1-2&rft.spage=105&rft.epage=108&rft.pages=105-108&rft.issn=0014-2999&rft_id=info:doi/10.1016/j.ejphar.2004.08.017&rft_dat=%3Cproquest_pubme%3E66941373%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=66941373&rft_id=info:pmid/15464095&rfr_iscdi=true |